As poor economic conditions continue to buffet the biopharma sector, tool vendors, especially publicly traded ones, have had to trim spending, cut staff, and lower expectations. Consequently, these steps have presented challenging questions to investors, R&D partners, and potential collaborators:
How does one company’s overall health compare with its competitors? Is it the right time to approach one firm over another for an R&D partnership? Will one collaboration stay on track or stall?
The following indices should serve as a snapshot of publicly traded genotyping companies. Though they are broad in scope, the indices are not a comprehensive review of these companies’ financial condition. Rather, the following graphs are designed to help readers learn how five critical statistics — revenue, R&D expenditures, cash on hand, R&D as a percentage of revenue and of cash — currently exist and have evolved over one year among competing companies.
Editors note: This chart comprises companies for whom genotyping services or platform sales represent a chief pillar of revenue and a major area of research and development expenses. The chart does not include companies whose genotyping play represents one component of a multi-faceted business plan.